Anixa Biosciences Inc. has announced the completion of enrollment in its Phase 1 clinical trial for a novel breast cancer vaccine, developed in partnership with Cleveland Clinic. The trial, which includes 35 women across three distinct patient cohorts, is fully funded by a grant from the U.S. Department of Defense. The vaccine aims to stimulate the immune system to target breast cancer before it can recur or develop. Encouraged by preliminary results showing a high level of immune response, Anixa is planning for Phase 2 trials and will submit trial data for presentation at a major scientific meeting.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。